Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy
Please view the file to learn more.
CYP2C12
Learn more about Genomadix, our technology, and molecular diagnostics.
Menu
CYP2C19 genotype-guided antiplatelet therapy promises and pitfalls
Please view the file to learn more.
POPular Genetics
POPular Genetics This randomized, prospective trial of 2,488 patients undergoing primary PCI with stent implantation assessed the use of a genotype-guided approach to oral P2Y12 inhibitor selection. This study showed that a genotype-guided approach to therapy was noninferior to standard treatment with ticagrelor or prasugrel with respect to thrombotic events, and resulted in a lower
The TAILOR-PCI Randomized Clinical Trial
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic Genotype-guided therapy resulted in 34% fewer adverse events after 12 months such as death, stroke, second heart attack, and stent thrombosis. Genotype-guided therapy resulted in 79% fewer adverse events in the first 3 months. According to principal investigator Dr. Naveen Pereira: “This finding suggests that the
Point-of-care genetic testing for personalisation of antiplatelet treatment
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic Rapid genetic testing after PCI can be effectively done at the bedside to identify CYP2C19*2 LOF allele carriers This prospective, randomized 200-patient study reported that tailored, genotype-guided treatment of CYP2C19*2 carriers can reduce high on-treatment platelet reactivity, which is commonly associated with increased risk for major
